Study summary

The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction compared to EOX alone.

Furthermore, sufficient binding of IMAB362 to the target cells is necessary for antitumoral activity. Thus, two dose levels ensuring a serum level above the in vitro predicted clinical efficacy threshold will be investigated.

Additional Study Details

Phase
2
Product
  • epirubicin
  • oxaliplatin
  • capecitabine
  • zolbetuximab
  • Type
    Interventional
    Masking
    N/A
    Enrollment number
    252
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site UKR015
      Poltava, Ukraine
      Completed
      Site GER010
      Dresden, Germany
      Completed
      Site RUS005
      Pyatigorsk, Russian Federation
      Withdrawn
      Site GER019
      Freiburg, Germany
      Withdrawn
      Site GER011
      Lebach, Germany
      Completed
      Site RUS001
      Moscow, Russian Federation
      Completed
      Site BUL002
      Varna, Bulgaria
      Completed
      Site RUS019
      Ryazan, Russian Federation
      Completed
      Site RUS012
      Orel, Russian Federation
      Completed
      Site UKR001
      Donetsk, Ukraine
      Completed
      Site GER013
      Pinneberg, Germany
      Completed
      Site RUS014
      Orenburg, Russian Federation
      Withdrawn
      Site LAT003
      Daugavpils, Latvia
      Completed
      Site RUS013
      Yaroslavl, Russian Federation
      Completed
      Site GER017
      Frankfurt, Germany
      Completed
      Site UKR009
      Zaporizhia, Ukraine
      Completed
      Site BUL004
      Plovdiv, Bulgaria
      Completed
      Site UKR010
      Uzhhorod, Ukraine
      Completed
      Site GER029-01
      Bochum, Germany
      Completed
      Site UKR006
      Lviv, Ukraine
      Completed
      Site LAT002
      Riga, Latvia
      Completed
      Site UKR002
      Donetsk, Ukraine
      Completed
      Site BUL001
      Sofia, Bulgaria
      Completed
      Site GER001
      Essen, Germany
      Completed
      Site BUL003
      Sofia, Bulgaria
      Completed
      Site GER020
      Leipzig, Germany
      Completed
      Site RUS007
      Ivanovo, Russian Federation
      Completed
      Site CZE002
      Olomouc, Czech Republic
      Completed
      Site RUS016
      Bryansk, Russian Federation
      Withdrawn
      Site CZE003
      Prague, Czech Republic
      Withdrawn
      Site RUS004
      Ekaterinburg, Russian Federation
      Completed
      Site UKR007
      Kyiv, Ukraine
      Completed
      Site BUL005
      Sofia, Bulgaria
      Completed
      Site RUS002
      Obninsk, Russian Federation
      Completed
      Site RUS003
      St.Petersburg, Russian Federation
      Completed
      Site RUS017
      Novgorod, Russian Federation
      Completed
      Site GER029
      Bochum, Germany
      Completed
      Site CZE001
      Znojmo, Czech Republic
      Withdrawn
      Site RUS025
      St. Petersburg, Russian Federation
      Completed
      Site RUS006
      Chelyabinsk, Russian Federation
      Completed
      Site GER016
      Münster, Germany
      Completed
      Site GER012
      Bielefeld, Germany
      Completed
      Site UKR005
      Kharkiv, Ukraine
      Completed
      Site RUS010
      St.Petersburg, Russian Federation
      Completed
      Site RUS015
      St.Petersburg, Russian Federation
      Withdrawn
      Site GER018
      Stade, Germany
      Completed
      Site RUS011
      Arkhangelsk, Russian Federation
      Completed
      Site RUS023
      Omsk, Russian Federation
      Completed
      Site RUS009
      Kursk, Russian Federation
      Completed
      Site GER005
      Halle/Saale, Germany
      Completed
      Site UKR004
      Simferopol, Ukraine
      Completed
      Site UKR011
      Sumy, Ukraine
      Completed
      Site LAT001
      Liepaja, Latvia
      Completed
      Site UKR008
      Ivano-Frankivsk, Ukraine
      Completed
      Site UKR003
      Dnipropetrovsk, Ukraine

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?